Showing results (1-10 of 24) with videos related to
Sort By:
Pageof 3
Acta Neuropsychiatrica|June 7, 2016
Misdiagnosed neurosyphilis associated with prolonged psychosisJustin Faden, John O'ReardonExpert Opinion on Pharmacotherapy|November 9, 2018
Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatmentJustin Faden, Leslie CitromeThe Medical Clinics of North America|November 19, 2022
Schizophrenia: One Name, Many Different ManifestationsJustin Faden, Leslie CitromeTherapeutic Advances in Psychopharmacology|November 23, 2020
Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?Justin Faden, Leslie CitromeSchizophrenia Research|January 30, 2024
A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorderJustin Faden, Leslie CitromeCurrent Medical Research and Opinion|March 24, 2025
A new paliperidone palmitate formulation: how is it different and where does it fit in our array of choices for long-acting formulations of risperidone and paliperidone?Justin Faden, Leslie CitromeNeuropsychiatric Disease and Treatment|September 10, 2019
Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adultsJustin Faden, Leslie CitromeExpert Review of Neurotherapeutics|March 31, 2022
Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?Justin Faden, Ryan Serdenes, Leslie CitromeTherapeutic Advances in Psychopharmacology|September 20, 2021
Asenapine: an atypical antipsychotic with atypical formulationsMeghan Musselman, Justin Faden, Leslie CitromeExpert Review of Neurotherapeutics|January 27, 2023
Sublingual dexmedetomidine: repurposing an anesthetic as an anti-agitation agentJustin Faden, Meghan Musselman, Leslie CitromePageof 3